Reata Pharmaceuticals

Last updated
Reata Pharmaceuticals, Inc.
Nasdaq: RETA
Industry Biotechnology
Founded1 January 2002  OOjs UI icon edit-ltr-progressive.svg
FateAcquired by Biogen
RevenueDecrease2.svg US $26.52 million (2019)
Increase2.svg US $53.59 million (2018) [1]
Owner
Website www.reatapharma.com

Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, [2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB. [3] The last CEO of Reata Pharmaceuticals was J. Warren Huff.

Contents

In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion. [4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq. [5]

Pipeline

The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in Reata’s portfolio.

Bardoxolone Methyl

Bardoxolone methyl was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for cancer, [6] Phase 2 and 3 studies for chronic kidney disease (CKD) associated with type 2 diabetes, [7] [8] and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension. [9] [10] [11]

RTA 408

Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds. The FDA approved Skyclarys (omoveloxolone) in 2023 for the treatment of Friedreich’s ataxia (FA), a hereditary neurological disorder that strikes during adolescence and leaves patients wheelchair-bound and often cuts short their lives. Skyclarys was also approved in the European Union, Canada, the UK, and Brazil in April 2025.

Skyclarys become the first drug approved for the condition, which affects roughly 5,000 who have been diagnosed in the United States and 22,000 worldwide. Preclinical studies demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities, [12] [13] as well as the potential to improve mitochondrial bioenergetics. [14] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology, [15] corneal endothelial cell loss associated with cataract surgery [16] Friedreich’s ataxia, [17] and mitochondrial myopathies. [18] [19]

Others

Reata was also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

Partnerships

Reata has a licensing agreement with Kyowa Hakko Kirin for development and commercialization of bardoxolone methyl for CKD and related indications in Japan, China, Taiwan, Korea, and other select Southeast Asian countries. [20]

Reata also has a licensing agreement with Abbvie for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with Kyowa Hakko Kirin. [21] Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators. [22]

References

  1. ↑ "RETA | Reata Pharmaceuticals Inc. Cl a Annual Income Statement".
  2. ↑ "Our Story". Reata Pharmaceuticals. Retrieved 5 August 2016.
  3. ↑ Sporn MB, Liby KT, Yore MM, et al. (2011). "New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress". J Nat Prod. 74 (3): 537–45. doi:10.1021/np100826q. PMC   3064114 . PMID   21309592.
  4. ↑ Mishra, Manas; Satija, Bhanvi; Satija, Bhanvi (2023-07-28). "Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio". Reuters. Retrieved 2023-07-28.
  5. ↑ "Biogen Completes Acquisition of Reata Pharmaceuticals". Yahoo! Finance. 26 September 2023. Retrieved 2023-10-05.
  6. ↑ Hong DS, Kurzrock R, Supko JG, et al. (2012). "A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas". Clin Cancer Res. 18 (12): 3396–406. doi:10.1158/1078-0432.CCR-11-2703. PMC   4494099 . PMID   22634319.
  7. ↑ Pergola PE, Raskin P, Toto RD, et al. (2011). "Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes". N Engl J Med. 365 (4): 327–36. doi: 10.1056/NEJMoa1105351 . PMID   21699484.
  8. ↑ de Zeeuw D, Akizawa T, Audhya P, et al. (2013). "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease". N Engl J Med. 369 (26): 2492–503. doi:10.1056/NEJMoa1306033. PMC   4496027 . PMID   24206459.
  9. ↑ "Reata Begins Enrollment For PAH – LARIAT Phase 2 Study Examining Bardoxolone Methyl for Treating Pulmonary Arterial Hypertension" . Retrieved 6 October 2014.
  10. ↑ "Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) (LARIAT)" . Retrieved 6 October 2014.
  11. ↑ Carroll, John (6 October 2014). "After a taste of disaster, Reata plans a comeback for bardoxolone".
  12. ↑ Reisman SA, Lee CY, Meyer CJ, et al. (2014). "Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin". Arch Dermatol Res. 306 (5): 447–57. doi:10.1007/s00403-013-1433-7. PMID   24362512. S2CID   25733020.
  13. ↑ Reisman SA, Lee CY, Meyer CJ, et al. (2014). "Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis". Radiat Res. 181 (5): 512–20. Bibcode:2014RadR..181..512R. doi: 10.1667/RR13578.1 . PMID   24720753. S2CID   23906747.
  14. ↑ Neymotin A, Calingasan NY, Wille E, et al. (2011). "Neuroprotective effect of Nrf2/ARE Activators, CDDO-ethylamide and CDDO-trifluoroethylamide in a Mouse Model of Amyotrophic Lateral Sclerosis". Free Radic Biol Med. 51 (1): 88–96. doi:10.1016/j.freeradbiomed.2011.03.027. PMC   3109235 . PMID   21457778.
  15. ↑ "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma)" . Retrieved 6 October 2014.
  16. ↑ "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD". April 15, 2015.
  17. ↑ "RTA 408 Capsules in Patients With Friedreich's Ataxia (MOXIe)" . Retrieved 6 October 2014.
  18. ↑ "RTA 408 Capsules in Patients With Mitochondrial Myopathy (MOTOR)" . Retrieved 6 October 2014.
  19. ↑ "Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies" . Retrieved 6 October 2014.
  20. ↑ "Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug" . Retrieved 6 October 2014.
  21. ↑ "Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl" . Retrieved 6 October 2014.
  22. ↑ Carroll, John. "Updated: Abbott bets $400M on mega-blockbuster future for Reata program" . Retrieved 6 October 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.